Ildong Pharmaceutical Co., Ltd. (249420.KS)
KRW 11350.0
(-5.42%)
KRW 11350.0
(-5.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -51.22 Billion KRW | 42.37% |
| 2022 | -80.49 Billion KRW | -84.38% |
| 2021 | -101.33 Billion KRW | -166.12% |
| 2020 | 22.6 Billion KRW | 33.98% |
| 2019 | 10.51 Billion KRW | -50.55% |
| 2018 | 50.75 Billion KRW | 19.92% |
| 2017 | 43.8 Billion KRW | 93.54% |
| 2016 | 23.23 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 7.18 Billion KRW | 806.71% |
| 2024 Q3 | 3.6 Billion KRW | -93.78% |
| 2024 Q1 | 6.38 Billion KRW | 2237.71% |
| 2023 Q2 | 55.68 Billion KRW | 2.91% |
| 2023 Q3 | 49.82 Billion KRW | -10.51% |
| 2023 Q4 | 3.82 Billion KRW | -92.33% |
| 2023 FY | - KRW | 42.37% |
| 2023 Q1 | 54.1 Billion KRW | 482.43% |
| 2022 Q4 | -14.14 Billion KRW | -17.75% |
| 2022 Q3 | -12.01 Billion KRW | 22.49% |
| 2022 Q2 | -15.5 Billion KRW | -720.85% |
| 2022 Q1 | -1.88 Billion KRW | 80.46% |
| 2022 FY | - KRW | -84.38% |
| 2021 Q4 | -9.66 Billion KRW | -32.86% |
| 2021 Q2 | -804.26 Million KRW | 86.31% |
| 2021 Q3 | -7.27 Billion KRW | -804.65% |
| 2021 FY | - KRW | -166.12% |
| 2021 Q1 | -5.87 Billion KRW | -603.15% |
| 2020 FY | - KRW | 33.98% |
| 2020 Q4 | 1.16 Billion KRW | -91.16% |
| 2020 Q3 | 13.2 Billion KRW | -11.01% |
| 2020 Q1 | 6.51 Billion KRW | 161.89% |
| 2020 Q2 | 14.83 Billion KRW | 127.95% |
| 2019 FY | - KRW | -50.55% |
| 2019 Q2 | 15.53 Billion KRW | 1.03% |
| 2019 Q3 | 6.26 Billion KRW | -59.69% |
| 2019 Q4 | -10.51 Billion KRW | -267.94% |
| 2019 Q1 | 15.38 Billion KRW | -12.01% |
| 2018 Q4 | 17.47 Billion KRW | 75.72% |
| 2018 Q1 | 12.64 Billion KRW | 18.12% |
| 2018 Q2 | 13.84 Billion KRW | 9.51% |
| 2018 FY | - KRW | 19.92% |
| 2018 Q3 | 9.94 Billion KRW | -28.17% |
| 2017 Q3 | 16.05 Billion KRW | 49.34% |
| 2017 Q2 | 10.75 Billion KRW | 44.31% |
| 2017 FY | - KRW | 93.54% |
| 2017 Q4 | 10.7 Billion KRW | -33.33% |
| 2017 Q1 | 7.45 Billion KRW | -52.44% |
| 2016 Q4 | 15.66 Billion KRW | 224.11% |
| 2016 FY | - KRW | 0.0% |
| 2016 Q3 | 4.83 Billion KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 1154.445% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 136.239% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 20.001% |
| HANDOK Inc. | 35.06 Billion KRW | 246.089% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | -4842.093% |
| Yuhan Corporation | 127.43 Billion KRW | 140.2% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 236.533% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | -136.212% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 115.844% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | 1126.557% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 438.852% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | 1597.483% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | 1231.771% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 244.361% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 1154.445% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | -177.333% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | 881.522% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | -3.929% |
| JW Holdings Corporation | 187.88 Billion KRW | 127.266% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 118.062% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 157.418% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | -38.206% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 487.813% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 533.117% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 374.612% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 1154.445% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 193.188% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 131.064% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 157.418% |
| Yuhan Corporation | 127.43 Billion KRW | 140.2% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 253.031% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 769.668% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 166.506% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 157.418% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 239.837% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 172.377% |
| CKD Bio Corp. | -1.63 Billion KRW | -3041.998% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 202.883% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 257.329% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 239.169% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | -38.206% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 182.249% |
| Boryung Corporation | 114.28 Billion KRW | 144.824% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | -67.587% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 438.852% |
| JW Lifescience Corporation | 50.82 Billion KRW | 200.786% |